GM2 Activator Protein Deep Dive
Lipid Transport Protein
Biological Context
GM2 Activator Protein (GM2AP) is a small (~17 kDa) lysosomal glycoprotein that acts as an essential cofactor for β-hexosaminidase A in the degradation of the ganglioside GM2. Because GM2 is embedded in the lysosomal membrane, β-hexosaminidase can’t access it directly — GM2AP extracts a single GM2 molecule from the membrane into a soluble, presented form that the enzyme can process.
Why it matters: Mutations in the gene encoding GM2AP (GM2A) cause AB-variant GM2 gangliosidosis, a severe neurodegenerative lysosomal storage disorder — phenotypically indistinguishable from Tay-Sachs and Sandhoff disease but caused by the loss of the activator rather than the enzyme. Engineered GM2AP variants with improved stability, or designed binders that stabilize folding-defective mutants, are of interest as both research tools and as prototypes for pharmacological chaperone therapies in lysosomal storage diseases.
The Goal: Design a binder that either (a) stabilizes folded GM2AP by engaging a surface patch, or (b) occludes the lipid-binding cavity as a research tool to probe GM2 extraction.
Interactive Structure
The viewer below shows the structure of GM2AP (PDB 1G13). Note that this particular deposition is the apo form — GM2AP + lipid structures (e.g., 1PU5, 1PUB) are better references for pocket residues.
- Rotate: Left-click and drag
- Zoom: Scroll wheel
- Pan: Right-click (or Ctrl+Left-click) and drag
Design Mission
Design a binder that engages GM2AP. Two reasonable strategies:
- Pocket occlusion: Target the lipid-binding cavity — blocks GM2 extraction.
- Surface stabilization: Target a well-folded surface patch away from the cavity — rescues destabilized disease-associated mutants.
Target Specifications
| Feature | Detail |
|---|---|
| Target Name | GM2 Activator Protein (GM2AP) |
| PDB ID (apo) | 1G13 |
| Alternative PDBs (with lipid) | 1PU5, 1PUB — GM2AP with bound platelet-activating factor / phosphatidylcholine |
| Target Chain | Chain A |
| Lipid-binding cavity residues (published, Wright 2000/2003) | V59, W63, F64, L65, M76, V100, V108, L122, V125, V126, L150, V153 — the hydrophobic core lining the cavity |
| Cavity rim / mouth | E29, R53, R80, I126 — more accessible from the outside and better hotspot candidates |
The 1G13 entry does not have a bound lipid, so the residue list here is taken from the published lipid-bound structures (1PU5, 1PUB; Wright et al. 2003) rather than computed from 1G13 itself. For hotspot-directed design, the rim residues (E29, R53, R80, I126) are what your binder will actually contact; the deep-pocket residues are inaccessible to a protein binder but define the pocket’s existence.
Strategy Tips
- Download PDB
1G13for the target structure, and inspect1PU5to see the lipid-bound conformation. - Clean the structure: Keep Chain A. The 1G13 deposition contains a crystallographic trimer — you only need one copy.
- Pick your strategy:
- Pocket-blocker: Pass rim residues (e.g.,
A29,A53,A80,A126) as hotspots — your binder sits over the cavity mouth and prevents lipid entry. - Stabilizer: Pick a convex surface patch away from the cavity (the C-terminal β-strand face is a reasonable candidate) and design a binder that staples across it.
- Pocket-blocker: Pass rim residues (e.g.,
- Watch out for flexibility: GM2AP undergoes a conformational change on lipid binding — the “mouth” opens. A binder designed against the apo state may not fit the open state and vice versa. If you have compute budget, design against both 1G13 and 1PU5 and pick a binder that works for both.
Reference
- Wright, C.S., Zhao, Q., Rastinejad, F. (2003). Structural analysis of lipid complexes of GM2-activator protein. J. Mol. Biol. 331, 951–964. doi:10.1016/S0022-2836(03)00809-X
- Wright, C.S., Li, S.C., Rastinejad, F. (2000). Crystal structure of human GM2-activator protein with a novel β-cup topology. J. Mol. Biol. 304, 411–422. doi:10.1006/jmbi.2000.4225 — primary citation for 1G13.